Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 15, 2019

CURE PHARMACEUTICAL HOLDING CORP.

(Exact name of small business issuer as specified in its charter)

Nevada

2834

37-1765151

(State or other jurisdiction of

incorporation or organization)

(Primary Standard Industrial

Classification Number)

(IRS Employer

Identification Number)

1620 Beacon Place, Oxnard, California 93033

(Address of principal executive offices)

(805) 824-0410

(Issuer's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors (the “Board”) of CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”), appointed Michael Redard as the Company’s Chief Financial Officer, effective on May 15, 2019.

The Company and Mr. Redard entered into an Employment Agreement (the “Agreement”) on May 19, 2019. Pursuant to the Agreement, Mr. Redard shall receive a base salary at a rate of $170,000.00 per annum. Additionally, the Company will grant Mr. Redard with a stock option to purchase up to 250,000 shares, priced at the current fair market value of the Company’s common stock on the date of the grant.

Mr. Redard, 60, is a seasoned executive with experience in finance, operations, sales, and business development in a variety of industries. He has significant experience in working with venture capital investors, private equity groups, and lenders. From 2011 to 2018, Mr. Redard was the Chief Financial Officer of Casa Pacifica, a provider of mental health services. After his tenure until his appointment at the Company, Mr. Redard was a principal at Redard Consulting. He has a B.S. in business administration from California Polytechnic State University, San Luis Obispo.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
10.1		Employment Agreement
99.1		Press release, dated May 20, 2019, announcing the appointment of Mr. Redard as Chief Financial Officer of CURE Pharmaceutical Holding Corp.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.